Latest Experimental cancer treatment Stories
To Begin I-124-CLR1404 (LIGHT) Phase 2 Imaging Trial in Brain Cancer in Early 2014 MADISON, Wis., May 16, 2013 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today provided an update on its product pipeline, including I-124-CLR1404 (LIGHT) positron emission tomography (PET) imaging agent for solid tumor indications, I-131-CLR1404 (HOT) cancer-targeted molecular...
UCL's Mark Emberton, MD, to Direct Premier Training Center for the Use of Advanced Imaging Capabilities to Localize Cancer and Deliver HIFU Treatment Using Tissue Preserving Techniques CHARLOTTE, N.C., May 2, 2013 /PRNewswire/ -- SonaCare Medical, a global leader in minimally invasive HIFU technologies, announced today that it has partnered with University College London (UCL) to create a HIFU Center of Excellence. The Center of Excellence will provide physician training and...
MADISON, Wisc., Nov. 5, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the closing of a private placement of equity securities to an affiliated entity of Renova Group for gross proceeds to Novelos of $2 million. The securities issued and sold in the private placement consisted of 2 million shares of Novelos' common stock, a warrant to purchase up to 1 million...
MADISON, Wis., Oct. 25, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that the University of Wisconsin Carbone Cancer Center (UWCCC), a leading oncology research institution, has enrolled the first patient in a Phase 1-2 positron emission tomography (PET) imaging trial of I-124-CLR1404 (LIGHT), a cancer-targeted PET imaging agent, in patients with nine solid...
MADISON, Wis., Aug. 28, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it is developing CLR1502 (GLOW2), a preclinical cancer-targeted optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. GLOW2 is expected to facilitate and enable diagnostic, staging, debulking and curative cancer surgeries intraoperatively in...
A new generation of cancer treatments based on nanotechnology is making its way out of the laboratory and into the clinic with the promise of targeting cancer cells while steering clear of healthy tissue, according to the current edition of Chemical & Engineering News (C&EN). C&EN is the weekly news magazine of the American Chemical Society (ACS), the world's largest scientific society. In the cover story, C&EN Senior Editor Bethany Halford explains that today's anti-cancer...
Potent new drug kills tumor cells in mice by clogging up their recycling system All cells have the ability to recycle unwanted or damaged proteins and reuse the building blocks as food. But cancer cells have ramped up the system, called autophagy, and rely on it to escape damage in the face of chemotherapy and other treatments. Now, researchers at the Perelman School of Medicine; the Abramson Cancer Center; and the School of Arts and Sciences, at the University of Pennsylvania, have...
Rice teams with MD Anderson, Baylor College of Medicine to explore drug and gene delivery Using light-harvesting nanoparticles to convert laser energy into “plasmonic nanobubbles,” researchers at Rice University, the University of Texas MD Anderson Cancer Center and Baylor College of Medicine (BCM) are developing new methods to inject drugs and genetic payloads directly into cancer cells. In tests on drug-resistant cancer cells, the researchers found that delivering chemotherapy drugs...
(Ivanhoe Newswire) "“ A novel discovery disguising nanoparticles as red blood cells allows them to invade the body without setting off an immune system response to deliver cancer-fighting drugs straight to the tumor.The method involves collecting the membrane from a red blood cell and wrapping it around a biodegradable polymer nanoparticle stuffed with a cocktail of small molecule drugs."This is the first work that combines the natural cell membrane with a synthetic nanoparticle for drug...
Researchers from the University of Hull have discovered a way to load up nanoparticles with large numbers of light-sensitive molecules to create a more effective form of photodynamic therapy (PDT) for treating cancer.Photodynamic therapy uses molecules which, when irradiated with light, cause irreparable damage to cells by creating toxic forms of oxygen, called reactive oxygen species. Most PDT works with individual light-sensitive molecules "“ but the new nanoparticles could each carry...
